[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"J&T Health and Wellness LLC\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":186},{"warningLetters":4,"total":185},[5,31,56,79,102,121,144,166],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":25,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},146,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-26T04:00:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faja-health-and-wellness-inc-729644-05182026\">Aja Health and Wellness Inc. \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Nonprescription\u002FOTC","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>729644\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sanjeev Parsad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aja Health and Wellness Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1199 West Pender Street, Suite 680\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vancouver\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V6E 2R1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:sparsad@ajahw.com\"> sparsad@ajahw.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@getaja.com\"> info@getaja.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Sanjeev Parsad:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website, https:\u002F\u002Feasemyheadache.com\u002F, in February 2026. Based on our review, your Aja Migraine Relief product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 331(a).\u003C\u002Fp>\u003Cp>This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Based on a review of your website, your Aja Migraine Relief is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>“Aja MIGRAINE RELIEF NASAL SPRAY . . . Natural Relief from Migraine Symptoms” [from the product label]\u003C\u002Fp>\u003Cp>“Natural fast-acting relief from migraines—pain, pressure, and discomfort. Uses proprietary BioFlora™ blend to ease pain and inflammation quickly….” [from the Aja Migraine Relief product webpage https:\u002F\u002Feasemyheadache.com\u002Fproducts\u002Faja-migraine-relief]\u003C\u002Fp>\u003Cp>“Testimonials Real people. Real relief. Here’s what they’re saying: I have . . . very painful migraines. I have been using this spray for weeks now and I feel immediate relief.” [from the Aja Migraine Relief testimonials webpage, https:\u002F\u002Feasemyheadache.com\u002Fpages\u002Ftestimonials]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, Aja Migraine Relief is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your Aja Migraine Relief, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, Aja Migraine Relief does not conform to the conditions specified in M013 for the reasons described below.\u003C\u002Fp>\u003Cp>Your Aja Migraine Relief is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\u003C\u002Fp>\u003Cp>In addition, your Aja Migraine Relief labeling includes intended uses that are not permitted for OTC internal analgesic products in M013. Specifically, claims such as “natural relief from migraine symptoms,” “ease . . . inflammation quickly,” and your product name, “Aja Migraine Relief,” that suggest Aja Migraine Relief is intended to treat migraines and inflammation go beyond the general intended uses for an OTC internal analgesic product and do not conform to the permitted uses set forth in M013.50(b).\u003C\u002Fp>\u003Cp>Furthermore, your Aja Migraine Relief product is formulated with an active ingredient that is not permitted for OTC internal analgesic drug products under M013.10. Specifically, according to the product labeling that appears on your website at the internet address described above, Aja Migraine Relief is formulated with the active ingredient BioFlora™ blend. We note that, although you do not explicitly identify BioFlora™ blend as an active ingredient, statements on your website show that it is an active ingredient because it is intended to furnish pharmacological activity for the treatment of a disease or condition.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> An example of such a statement includes, “Uses proprietary BioFlora™ blend to ease pain and inflammation quickly.” Consequently, this ingredient is an active ingredient and, because it is not an active ingredient permitted under M013.10, your Aja Migraine Relief product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\u003C\u002Fp>\u003Cp>Thus, your Aja Migraine Relief product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, Aja Migraine Relief is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729644” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs @ FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that Aja Migraine Relief is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n729644\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nSanjeev Parsad\n\nRecipient Title\n\nPresident and CEO\n\nAja Health and Wellness Inc.\n\n1199 West Pender Street, Suite 680\n\nVancouver BC V6E 2R1\n\nCanada\n\nsparsad@ajahw.com\n\ninfo@getaja.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\nTo Sanjeev Parsad:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of your website, https:\u002F\u002Feasemyheadache.com\u002F, in February 2026. Based on our review, your Aja Migraine Relief product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). As explained further below, introducing or delivering this product for introduction into interstate commerce is prohibited under sections 301(d) and 301(a) of the FD&C Act, 21 U.S.C. 331(d) and 331(a).\nThis review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nUnapproved New Drug Violations\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nBased on a review of your website, your Aja Migraine Relief is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\n“Aja MIGRAINE RELIEF NASAL SPRAY . . . Natural Relief from Migraine Symptoms” [from the product label]\n“Natural fast-acting relief from migraines—pain, pressure, and discomfort. Uses proprietary BioFlora™ blend to ease pain and inflammation quickly….” [from the Aja Migraine Relief product webpage https:\u002F\u002Feasemyheadache.com\u002Fproducts\u002Faja-migraine-relief]\n“Testimonials Real people. Real relief. Here’s what they’re saying: I have . . . very painful migraines. I have been using this spray for weeks now and I feel immediate relief.” [from the Aja Migraine Relief testimonials webpage, https:\u002F\u002Feasemyheadache.com\u002Fpages\u002Ftestimonials]\nBased on the above labeling evidence, Aja Migraine Relief is intended for use as an internal analgesic drug product. As described below, this drug product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this drug product identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription internal analgesic drug products, such as your Aja Migraine Relief, in order to be GRASE and not a new drug, the product must, among other things, conform to the conditions in the applicable OTC monograph, here M013: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use (hereinafter “M013”).1 However, Aja Migraine Relief does not conform to the conditions specified in M013 for the reasons described below.\nYour Aja Migraine Relief is intended to be applied inside the nostrils. Under M013.1, only an OTC internal analgesic drug product in a form suitable for oral administration is generally recognized as safe and effective if it meets the conditions of M013. Thus, your internal analgesic drug product intended for administration inside the nostrils, does not conform to the conditions of M013.\nIn addition, your Aja Migraine Relief labeling includes intended uses that are not permitted for OTC internal analgesic products in M013. Specifically, claims such as “natural relief from migraine symptoms,” “ease . . . inflammation quickly,” and your product name, “Aja Migraine Relief,” that suggest Aja Migraine Relief is intended to treat migraines and inflammation go beyond the general intended uses for an OTC internal analgesic product and do not conform to the permitted uses set forth in M013.50(b).\nFurthermore, your Aja Migraine Relief product is formulated with an active ingredient that is not permitted for OTC internal analgesic drug products under M013.10. Specifically, according to the product labeling that appears on your website at the internet address described above, Aja Migraine Relief is formulated with the active ingredient BioFlora™ blend. We note that, although you do not explicitly identify BioFlora™ blend as an active ingredient, statements on your website show that it is an active ingredient because it is intended to furnish pharmacological activity for the treatment of a disease or condition.2 An example of such a statement includes, “Uses proprietary BioFlora™ blend to ease pain and inflammation quickly.” Consequently, this ingredient is an active ingredient and, because it is not an active ingredient permitted under M013.10, your Aja Migraine Relief product does not conform with the conditions for lawful marketing of an OTC internal analgesic drug product as set forth in M013.\nThus, your Aja Migraine Relief product does not comply with the applicable conditions specified in M013 and has not otherwise been found GRASE.3 Accordingly, this product is a new drug within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which this product would be legally marketed without an approved application. Because there is no approved application in effect for this product, this product is an unapproved new drug.\nThe introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, Aja Migraine Relief is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because this product is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “729644” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________________\n1 M013 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000027, available at FDA’s website OTC Monographs @ FDA [https:\u002F\u002Fdps.fda.gov\u002Fomuf].\n2 See 21 CFR 201.66(b)(2), which defines an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of humans.”\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that Aja Migraine Relief is GRASE for use under the conditions prescribed, recommended, or suggested in its labeling, nor has FDA determined this drug product to be GRASE pursuant to an order issued under section 505G(b).","Aja Health and Wellness Inc.","aja-health-and-wellness-inc-729644-05182026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faja-health-and-wellness-inc-729644-05182026","2026-10-26T08:07:51.687537+00:00","Warning Letter","Issued","2026-05-26","729644","Drugs Over-the-Counter Drugs","Sanjeev Parsad","2026-08-19T04:39:34.905+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2026-05-18",{"id":32,"raw":33,"subject":38,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":47,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":51,"issuing_office":37,"recipient_name":52,"body_fetched_at":53,"delivery_method":54,"recipient_title":19,"reference_number":19,"action_taken_date":55,"medical_device_id":19,"response_letter_date":19},2837,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2022-03-01T14:20:00Z\">03\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-17T05:00:00Z\">02\u002F17\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvital-health-wellness-618743-02172022\">Vital Health &amp; Wellness\u003C\u002Fa>","Office of Human and Animal Foods Operations-East V","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvital-health-wellness-618743-04282023\">\u003Ctime datetime=\"2023-05-08T04:00:00Z\">05\u002F08\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher A. Williamson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vital Health &amp; Wellness\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>800 Industrial Park Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Trenton\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38382\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Foods Operations-East V\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 618743\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 17, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Williamson:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your tea processing facility, located at 800 Industrial Park Dr., Trenton, TN 38382 on August 23 and 30, 2021. During the inspection, FDA investigators collected your label for the product Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea. FDA also reviewed your website at www.vitalhealthandwellness.net in November 2021 and February 2022 and determined that you take orders there for your Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea. The claims on your website and product label establish that your Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>An example on your product label of some of the claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>• “MAY BE BENEFICIAL FOR:… ACID REFLUX…HIGH BLOOD PRESSURE”\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims on your website’s “Ingredients” page that provide evidence that your product is intended for use as a drug include (the “Ingredients” page identifies Holy Thistle, Persimmon leaves, Malva leaves, Marsh Mallow leaves, Blessed Thistle, Papaya, Ginger and Chamomile as ingredients in Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea):\u003C\u002Fp>\n\n\u003Cp>• Persimmon leaves\u003Cbr>\n&nbsp; o “ . . . Persimmon leaves have anti-hypertensive, anti-carcinogenic, and anti-mutagen properties.”\u003Cbr>\n&nbsp; o “The [persimmon] leaf … is anti hemorrhagic (stops bleeding), is an effective remedy for hemorrhoids, and strengthens weak blood vessels such as spider veins or varicose veins.”\u003Cbr>\n• Holy thistle\u003Cbr>\n&nbsp; o “Holy thistle has been used medicinally for over 2000 years, most commonly for the treatment of liver disorders such as jaundice, and gallbladder disorders; but also for lactation problems, disorders of the spleen, psoriasis, and mushroom poisoning.”\u003Cbr>\n&nbsp; o “[Holy thistle] has recently been used by HIV-positive patients to protect the liver from diseases such as hepatitis and damage from the drugs taken for HIV or AIDS. . . . Silymarin[, a flavonoid in holy thistle,] has also been shown to regenerate injured liver cells.”\u003Cbr>\n&nbsp; o “Holy Thistle products are popular in Europe and the United States for various types of liver disease, being able to counteract the harmful actions of alcohol on the liver (cirrhosis), and helping the liver return to a healthy state when an alcoholic stops drinking. Some clinical trials indicate that it may improve quality of life and even increase life expectancy in patients with cirrhosis of the liver.”\u003Cbr>\n&nbsp; o “ . . . [D]rinking a cup of Holy Thistle tea twice a day can cure chronic headaches. It is also used for…constipation relief. It is very effective for dropsy….”\u003Cbr>\n• Malva leaves\u003Cbr>\n&nbsp; o “Malva Leaf teas are used in the treatment of renal disorders… and diarrhea. Malva Leaf has been used to treat stomachache, gastroenteritis, irritable bowel, and conditions of the spleen.”\u003Cbr>\n• Marshmallow leaves\u003Cbr>\n&nbsp; o “ . . . Marsh Mallow swells up and becomes slick when it is exposed to fluids. The resulting slippery material coats the linings of the mouth, throat, and stomach to relieve irritation and control coughing associated with respiratory conditions such as smoker’s cough.”\u003Cbr>\n&nbsp; o “ . . . Marsh Mallow has been used to treat sore throats and to alleviate heartburn...”\u003Cbr>\n&nbsp; o “ . . . Marsh Mallow is listed for gastroenteritis, peptic and duodenal ulcers, colitis, and enteritis.”\u003Cbr>\n• Blessed thistle\u003Cbr>\n&nbsp; o “It was cultivated in monastery gardens as a cure for smallpox . . ..”\u003Cbr>\n&nbsp; o “Blessed Thistle has been used for smallpox, malaria, fever, anorexia, dyspepsia, indigestion, constipation, and flatulence.”\u003Cbr>\n&nbsp; o “More recently it has shown to be useful for indigestion, heartburn . . . . Blessed Thistle helps increase appetite in people with digestion or eating disorders such as anorexia . . . .”\u003Cbr>\n&nbsp; o “In herbal medicine, Blessed Thistle is used for cancer, infections, inflammation, gallbladder disease, jaundice, liver disorders, cervical dysplasia, heart ailments, skin ulcers, yeast infections, and diarrhea.”\u003Cbr>\n• Papaya\u003Cbr>\n&nbsp; o “It is rich in Anti-oxidants, the B vitamins, folate and pantothenic acid; and the minerals potassium and magnesium, and fiber. Together, ‘these nutrients…provide protection against colon cancer.’”\u003Cbr>\n&nbsp; o “ . . . [P]apaya contains the digestive enzyme, papain, which is used…to treat…allergies.”\u003Cbr>\n&nbsp; o “Papaya may therefore be a healthy fruit choice for preventing such illnesses as recurrent ear infections, colds, and flu.”\u003Cbr>\n• Ginger\u003Cbr>\n&nbsp; o “For over two thousand years Chinese Medicine has recommended ginger to treat a number of health problems including … coughing, vomiting, diarrhea, and rheumatism.”\u003Cbr>\n&nbsp; o “Ginger is also used in the Ayurvedic and Tibetan systems of medicine for the treatment of inflammatory joint diseases such as arthritis, rheumatism . . . .”\u003Cbr>\n&nbsp; o “Ginger may also ease sore throats, headaches, ulcerative colitis, some types of arthritis pain, and fevers and aches caused by colds and flu.”\u003Cbr>\n• Chamomile\u003Cbr>\n&nbsp; o “This bittersweet herb acts medicinally as an anodyne, anti-inflammatory, antibacterial, anti-allergenic, and sedative.”\u003Cbr>\n&nbsp; o “Chamomile tea can be used to treat … gastrointestinal spasms, inflammatory disease of the gastrointestinal tract, and to treat coughs and colds, fevers and bronchitis.”\u003Cbr>\n&nbsp; o “Chamomile’s mildly sedating and muscle-relaxing effects can help those who suffer from insomnia . . . . ”\u003Cbr>\n&nbsp; o “Chamomile helps to relieve nausea, heartburn . . . . It may also be useful in the treatment of diverticular disorders and inflammatory bowel conditions such as Crohn’s disease.”\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims on your website’s “TEA AND CANCER PREVENTION – NATIONAL CANCER INSTITUTE” page that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>• “More than 50 epidemiologic studies of the association between tea consumption and cancer risk have been published since 2006. The results of these studies have often been inconsistent, but some have linked tea consumption to reduced risks of cancers of the colon, breast, ovary, prostate, and lung. Green tea contains substances called polyphenols, which scientists think contribute to its anti-cancer activity. Laboratory studies of one polyphenol, catechin epigallocatechin-3-gallate (EGCG), show that it may interfere with several of the processes involved in cell replication, causing tumor cell death (apoptosis). Aug 16, 2017”\u003C\u002Fp>\n\n\u003Cp>Your product Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Vi-tal Health &amp; Wellness brand Dr. Miller’s Holistic Premium Holy Tea fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nChristopher A. Williamson\n\nRecipient Title\n\nOwner\n\nVital Health & Wellness\n\n800 Industrial Park Dr.\n\nTrenton, TN 38382\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Foods Operations-East V\n\nUnited States\n\nWARNING LETTER 618743\n\nFebruary 17, 2022\n\nDear Mr. Williamson:\n\nThe U.S. Food and Drug Administration (FDA) inspected your tea processing facility, located at 800 Industrial Park Dr., Trenton, TN 38382 on August 23 and 30, 2021. During the inspection, FDA investigators collected your label for the product Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea. FDA also reviewed your website at www.vitalhealthandwellness.net in November 2021 and February 2022 and determined that you take orders there for your Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea. The claims on your website and product label establish that your Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAn example on your product label of some of the claims that provide evidence that your product is intended for use as a drug include:\n\n• “MAY BE BENEFICIAL FOR:… ACID REFLUX…HIGH BLOOD PRESSURE”\n\nExamples of some of the claims on your website’s “Ingredients” page that provide evidence that your product is intended for use as a drug include (the “Ingredients” page identifies Holy Thistle, Persimmon leaves, Malva leaves, Marsh Mallow leaves, Blessed Thistle, Papaya, Ginger and Chamomile as ingredients in Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea):\n\n• Persimmon leaves\n\no “ . . . Persimmon leaves have anti-hypertensive, anti-carcinogenic, and anti-mutagen properties.”\n\no “The [persimmon] leaf … is anti hemorrhagic (stops bleeding), is an effective remedy for hemorrhoids, and strengthens weak blood vessels such as spider veins or varicose veins.”\n\n• Holy thistle\n\no “Holy thistle has been used medicinally for over 2000 years, most commonly for the treatment of liver disorders such as jaundice, and gallbladder disorders; but also for lactation problems, disorders of the spleen, psoriasis, and mushroom poisoning.”\n\no “[Holy thistle] has recently been used by HIV-positive patients to protect the liver from diseases such as hepatitis and damage from the drugs taken for HIV or AIDS. . . . Silymarin[, a flavonoid in holy thistle,] has also been shown to regenerate injured liver cells.”\n\no “Holy Thistle products are popular in Europe and the United States for various types of liver disease, being able to counteract the harmful actions of alcohol on the liver (cirrhosis), and helping the liver return to a healthy state when an alcoholic stops drinking. Some clinical trials indicate that it may improve quality of life and even increase life expectancy in patients with cirrhosis of the liver.”\n\no “ . . . [D]rinking a cup of Holy Thistle tea twice a day can cure chronic headaches. It is also used for…constipation relief. It is very effective for dropsy….”\n\n• Malva leaves\n\no “Malva Leaf teas are used in the treatment of renal disorders… and diarrhea. Malva Leaf has been used to treat stomachache, gastroenteritis, irritable bowel, and conditions of the spleen.”\n\n• Marshmallow leaves\n\no “ . . . Marsh Mallow swells up and becomes slick when it is exposed to fluids. The resulting slippery material coats the linings of the mouth, throat, and stomach to relieve irritation and control coughing associated with respiratory conditions such as smoker’s cough.”\n\no “ . . . Marsh Mallow has been used to treat sore throats and to alleviate heartburn...”\n\no “ . . . Marsh Mallow is listed for gastroenteritis, peptic and duodenal ulcers, colitis, and enteritis.”\n\n• Blessed thistle\n\no “It was cultivated in monastery gardens as a cure for smallpox . . ..”\n\no “Blessed Thistle has been used for smallpox, malaria, fever, anorexia, dyspepsia, indigestion, constipation, and flatulence.”\n\no “More recently it has shown to be useful for indigestion, heartburn . . . . Blessed Thistle helps increase appetite in people with digestion or eating disorders such as anorexia . . . .”\n\no “In herbal medicine, Blessed Thistle is used for cancer, infections, inflammation, gallbladder disease, jaundice, liver disorders, cervical dysplasia, heart ailments, skin ulcers, yeast infections, and diarrhea.”\n\n• Papaya\n\no “It is rich in Anti-oxidants, the B vitamins, folate and pantothenic acid; and the minerals potassium and magnesium, and fiber. Together, ‘these nutrients…provide protection against colon cancer.’”\n\no “ . . . [P]apaya contains the digestive enzyme, papain, which is used…to treat…allergies.”\n\no “Papaya may therefore be a healthy fruit choice for preventing such illnesses as recurrent ear infections, colds, and flu.”\n\n• Ginger\n\no “For over two thousand years Chinese Medicine has recommended ginger to treat a number of health problems including … coughing, vomiting, diarrhea, and rheumatism.”\n\no “Ginger is also used in the Ayurvedic and Tibetan systems of medicine for the treatment of inflammatory joint diseases such as arthritis, rheumatism . . . .”\n\no “Ginger may also ease sore throats, headaches, ulcerative colitis, some types of arthritis pain, and fevers and aches caused by colds and flu.”\n\n• Chamomile\n\no “This bittersweet herb acts medicinally as an anodyne, anti-inflammatory, antibacterial, anti-allergenic, and sedative.”\n\no “Chamomile tea can be used to treat … gastrointestinal spasms, inflammatory disease of the gastrointestinal tract, and to treat coughs and colds, fevers and bronchitis.”\n\no “Chamomile’s mildly sedating and muscle-relaxing effects can help those who suffer from insomnia . . . . ”\n\no “Chamomile helps to relieve nausea, heartburn . . . . It may also be useful in the treatment of diverticular disorders and inflammatory bowel conditions such as Crohn’s disease.”\n\nExamples of some of the claims on your website’s “TEA AND CANCER PREVENTION – NATIONAL CANCER INSTITUTE” page that provide evidence that your product is intended for use as a drug include:\n\n• “More than 50 epidemiologic studies of the association between tea consumption and cancer risk have been published since 2006. The results of these studies have often been inconsistent, but some have linked tea consumption to reduced risks of cancers of the colon, breast, ovary, prostate, and lung. Green tea contains substances called polyphenols, which scientists think contribute to its anti-cancer activity. Laboratory studies of one polyphenol, catechin epigallocatechin-3-gallate (EGCG), show that it may interfere with several of the processes involved in cell replication, causing tumor cell death (apoptosis). Aug 16, 2017”\n\nYour product Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Vi-tal Health & Wellness brand Dr. Miller’s Holistic Premium Holy Tea fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Vital Health & Wellness","vital-health-wellness-618743-02172022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvital-health-wellness-618743-02172022","2026-10-26T08:10:28.399544+00:00","Closed Out","2022-03-01","618743","Food & Beverages","2023-05-08","Christopher A. Williamson","2026-08-20T02:08:32.8+00:00","VIA UNITED PARCEL SERVICE","2022-02-17",{"id":57,"raw":58,"subject":64,"body_html":65,"body_text":66,"firm_name":67,"letter_id":68,"created_at":18,"fei_number":19,"letter_url":69,"updated_at":70,"action_type":22,"case_status":47,"posted_date":71,"marcs_cms_no":72,"product_type":73,"closeout_date":74,"issuing_office":11,"recipient_name":75,"body_fetched_at":76,"delivery_method":77,"recipient_title":19,"reference_number":19,"action_taken_date":78,"medical_device_id":19,"response_letter_date":19},222,[59,60,61,11,62,13,63,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-09T05:00:00Z\">02\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026\">Thrive Health and Wellness, LLC dba Thrive Health Solutions \u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-07272026\">\u003Ctime datetime=\"2026-08-06T04:00:00Z\">08\u002F06\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Doug Hatch\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Thrive Health and Wellness, LLC dba Thrive Health Solutions \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>88 Inverness Circle East, Ste A-204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Englewood\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80112-5521\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 714891\u003C\u002Fp>\u003Cp>February 9, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Hatch:\u003C\u002Fp>\u003Cp>From March 25, 2025, to April 3, 2025, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Thrive Health and Wellness, LLC dba Thrive Health Solutions, located at 88 Inverness Circle E Ste A-204, Englewood, CO 80112. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your firm on April 3, 2025. FDA acknowledges receipt of your facility’s response, dated April 22, 2025. FDA further acknowledges that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. FDA also acknowledges that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\u003Cp>1. Your personnel were observed conducting aseptic operations outside of a certified ISO 5 area. More specifically, your personnel filled sterile drug products into syringes on a benchtop table located in an unclassified room that shared the workspace with a blood sample centrifuge. These drug products were not intended for immediate administration to patients but were distributed for future administration outside your facility.\u003C\u002Fp>\u003Cp>2. Your personnel performing sterile operations have never performed media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\u003Cp>3. Your aseptic processing and surrounding areas had difficult to clean equipment and surfaces. For example, your entire facility flooring was covered with carpet.\u003C\u002Fp>\u003Cp>4. Your personnel engaged in aseptic processing while wearing non-sterile gloves and with exposed hair and skin.\u003C\u002Fp>\u003Cp>5. Your firm failed to use a sporicidal agent as part of your disinfection program for the aseptic processing area and used non-sterile wipes to clean within the area where drug products were filled into syringes.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for the drug products that you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> These products are unapproved new drugs under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)]. A new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505\u003Cbr>of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application is prohibited under section 301(d) of the FDCA [21 U.S.C. § 331(d)].\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s response to the Form FDA 483. We acknowledge that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. We also acknowledge that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>If you decide to resume operations to produce sterile drug products not intended for immediate use, you should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations, or you may inform us that you do not intend to resume production of sterile drug products not intended for immediate use. If you intend to resume production of sterile drug products not intended for immediate use in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any drugs intended or expected to be sterile in the future.\u003C\u002Fp>\u003Cp>Your response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (# 714891) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The specific products repackaged by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3 \u003C\u002Fstrong>\u003C\u002Fem>Drugs that are repackaged are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. For additional information, you may wish to review FDA’s 2017 guidance document, “Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities.” More specifically, the guidance sets forth conditions under which FDA does not intend to take action against drug products repackaged by pharmacies and outsourcing facilities for certain violations of the FDCA. Such conditions include, but are not limited to, the drug product that is being repackaged is a prescription drug product that (1) is approved under section 505 of the FDCA; or (2) is an unapproved drug product that appears on the drug shortage list in effect under section 506E of the FDCA, and the repackaged drug product is distributed during any period in which it is listed on that drug shortage list or during the 30 days following such period.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDoug Hatch\n\nRecipient Title\n\nOwner\n\nThrive Health and Wellness, LLC dba Thrive Health Solutions\n\n88 Inverness Circle East, Ste A-204\n\nEnglewood, CO 80112-5521\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 714891\nFebruary 9, 2026\nDear Mr. Hatch:\nFrom March 25, 2025, to April 3, 2025, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Thrive Health and Wellness, LLC dba Thrive Health Solutions, located at 88 Inverness Circle E Ste A-204, Englewood, CO 80112. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your firm on April 3, 2025. FDA acknowledges receipt of your facility’s response, dated April 22, 2025. FDA further acknowledges that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. FDA also acknowledges that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\nA. Compounded Drug Products Under the FDCA\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1\nB. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n1. Your personnel were observed conducting aseptic operations outside of a certified ISO 5 area. More specifically, your personnel filled sterile drug products into syringes on a benchtop table located in an unclassified room that shared the workspace with a blood sample centrifuge. These drug products were not intended for immediate administration to patients but were distributed for future administration outside your facility.\n2. Your personnel performing sterile operations have never performed media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n3. Your aseptic processing and surrounding areas had difficult to clean equipment and surfaces. For example, your entire facility flooring was covered with carpet.\n4. Your personnel engaged in aseptic processing while wearing non-sterile gloves and with exposed hair and skin.\n5. Your firm failed to use a sporicidal agent as part of your disinfection program for the aseptic processing area and used non-sterile wipes to clean within the area where drug products were filled into syringes.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for the drug products that you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL.2 These products are unapproved new drugs under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)]. A new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505\nof the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application is prohibited under section 301(d) of the FDCA [21 U.S.C. § 331(d)].3\nMisbranded Drug Products\nThe drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nC. Corrective Actions\nWe have reviewed your facility’s response to the Form FDA 483. We acknowledge that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. We also acknowledge that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nIf you decide to resume operations to produce sterile drug products not intended for immediate use, you should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations, or you may inform us that you do not intend to resume production of sterile drug products not intended for immediate use. If you intend to resume production of sterile drug products not intended for immediate use in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any drugs intended or expected to be sterile in the future.\nYour response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (# 714891) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n2 The specific products repackaged by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n3 Drugs that are repackaged are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. For additional information, you may wish to review FDA’s 2017 guidance document, “Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities.” More specifically, the guidance sets forth conditions under which FDA does not intend to take action against drug products repackaged by pharmacies and outsourcing facilities for certain violations of the FDCA. Such conditions include, but are not limited to, the drug product that is being repackaged is a prescription drug product that (1) is approved under section 505 of the FDCA; or (2) is an unapproved drug product that appears on the drug shortage list in effect under section 506E of the FDCA, and the repackaged drug product is distributed during any period in which it is listed on that drug shortage list or during the 30 days following such period.\n4 The drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Thrive Health and Wellness, LLC dba Thrive Health Solutions","thrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026","2026-10-26T08:10:11.920103+00:00","2026-04-21","714891","Drugs","2026-08-06","Doug Hatch","2026-08-19T04:47:00.798+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-02-09",{"id":80,"raw":81,"subject":38,"body_html":87,"body_text":88,"firm_name":89,"letter_id":90,"created_at":91,"fei_number":19,"letter_url":92,"updated_at":93,"action_type":22,"case_status":47,"posted_date":94,"marcs_cms_no":95,"product_type":50,"closeout_date":96,"issuing_office":97,"recipient_name":98,"body_fetched_at":99,"delivery_method":100,"recipient_title":19,"reference_number":19,"action_taken_date":101,"medical_device_id":19,"response_letter_date":19},2187,[82,83,84,85,38,13,86,13],"\u003Ctime datetime=\"2023-02-28T14:20:00Z\">02\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-02-03T05:00:00Z\">02\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjackson-health-wellness-clinic-646556-02032023\">Jackson Health &amp; Wellness Clinic\u003C\u002Fa>"," Division of Human and Animal Food Operations East V ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjackson-health-wellness-clinic-646556-08012023\">\u003Ctime datetime=\"2023-08-04T04:00:00Z\">08\u002F04\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William (Bill) Miller\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jackson Health &amp; Wellness Clinic\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>123 Devonshire Sq, Ste B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jackson\u003C\u002Fspan>, \u003Cspan>TN\u003C\u002Fspan> \u003Cspan>38305\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter # 646556\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>February 3, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Miller:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your websites at the Internet addresses www.drmillersclinic.com\u002Flanding\u002F and www.drmillersclinic.com\u002Findex.html in October 2022 and January 2023, and has determined that you take orders there for the products Dr. Miller’s Holy Tea, Dr. Miller’s Super Holy Tea, Dr. Miller’s Ultimate Tea, Dr. Miller’s Be Free Spring Clean Herbal Detox (pills and tea), and Dr. Miller’s Youthin Fatburners. The claims on your websites establish the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>Dr. Miller’s Holy Tea and Super Holy Tea products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[H]elp relieve digestive ailments such as Acid Reflux (GERD), irritable bowel syndrome (IBS), Crohn's Disease, Diverticulitis, Colitis”\u003C\u002Fli>\n\t\u003Cli>“[A]id in reducing high LDL cholesterol and hypertension”\u003C\u002Fli>\n\t\u003Cli>“[R]emove parasites such as worms and flukes from the colon”\u003C\u002Fli>\n\t\u003Cli>“End constipation...and hemorrhoids”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Dr. Miller’s Ultimate Tea\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The Ultimate Tea may be beneficial for:... (Constipation… Acid Reflux), Lowers High Blood Pressure, Lowers Cholesterol ... Helps Spastic Colon, Helps Crohn’s Disease”\u003C\u002Fli>\n\t\u003Cli>“[B]eneficial for: Detoxifies ( … Parasites, Bacteria…)”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Dr Miller’s Be Free Spring Clean Herbal Detox\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[R]emoves … Flukes, Mold, Parasites, Viruses, and Bacteria.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Dr Miller’s Youthin Fatburners\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Regular use of Youthin Fat Burners may help control High Blood Pressure and Cholesterol”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Dr. Miller’s Holy Tea for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[H]as had terrible migraines for the past 10 years… After a couple of months drinking Dr. Miller's Tea, he no longer has the migraines.”\u003C\u002Fli>\n\t\u003Cli>“I used to have terrible knife-like sharp pains in my stomach from the Crohn's and IBS, and a great deal of discomfort from the acid reflux. Dr. Miller's Holy Tea has cleared all of this up….”\u003C\u002Fli>\n\t\u003Cli>“[A]nd no longer have the bloating and acid reflux I was having.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Dr. Miller’s Holy Tea, Dr. Miller’s Super Holy Tea, Dr. Miller’s Ultimate Tea, and Dr Miller’s Youthin Fatburners are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Dr. Miller’s Holy Tea, Dr. Miller’s Super Holy Tea, Dr. Miller’s Ultimate Tea, and Dr Miller’s Youthin Fatburners fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nWilliam (Bill) Miller\n\nRecipient Title\n\nOwner\n\nJackson Health & Wellness Clinic\n\n123 Devonshire Sq, Ste B\n\nJackson, TN 38305\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nWarning Letter # 646556\n\nFebruary 3, 2023\n\nDear Mr. Miller:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your websites at the Internet addresses www.drmillersclinic.com\u002Flanding\u002F and www.drmillersclinic.com\u002Findex.html in October 2022 and January 2023, and has determined that you take orders there for the products Dr. Miller’s Holy Tea, Dr. Miller’s Super Holy Tea, Dr. Miller’s Ultimate Tea, Dr. Miller’s Be Free Spring Clean Herbal Detox (pills and tea), and Dr. Miller’s Youthin Fatburners. The claims on your websites establish the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nDr. Miller’s Holy Tea and Super Holy Tea products\n\n“[H]elp relieve digestive ailments such as Acid Reflux (GERD), irritable bowel syndrome (IBS), Crohn's Disease, Diverticulitis, Colitis”\n\n“[A]id in reducing high LDL cholesterol and hypertension”\n\n“[R]emove parasites such as worms and flukes from the colon”\n\n“End constipation...and hemorrhoids”\n\nDr. Miller’s Ultimate Tea\n\n“The Ultimate Tea may be beneficial for:... (Constipation… Acid Reflux), Lowers High Blood Pressure, Lowers Cholesterol ... Helps Spastic Colon, Helps Crohn’s Disease”\n\n“[B]eneficial for: Detoxifies ( … Parasites, Bacteria…)”\n\nDr Miller’s Be Free Spring Clean Herbal Detox\n\n“[R]emoves … Flukes, Mold, Parasites, Viruses, and Bacteria.”\n\nDr Miller’s Youthin Fatburners\n\n“Regular use of Youthin Fat Burners may help control High Blood Pressure and Cholesterol”\n\nYour website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of Dr. Miller’s Holy Tea for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\n“[H]as had terrible migraines for the past 10 years… After a couple of months drinking Dr. Miller's Tea, he no longer has the migraines.”\n\n“I used to have terrible knife-like sharp pains in my stomach from the Crohn's and IBS, and a great deal of discomfort from the acid reflux. Dr. Miller's Holy Tea has cleared all of this up….”\n\n“[A]nd no longer have the bloating and acid reflux I was having.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Dr. Miller’s Holy Tea, Dr. Miller’s Super Holy Tea, Dr. Miller’s Ultimate Tea, and Dr Miller’s Youthin Fatburners are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Dr. Miller’s Holy Tea, Dr. Miller’s Super Holy Tea, Dr. Miller’s Ultimate Tea, and Dr Miller’s Youthin Fatburners fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Jackson Health & Wellness Clinic","jackson-health-wellness-clinic-646556-02032023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjackson-health-wellness-clinic-646556-02032023","2026-10-26T08:09:02.349224+00:00","2023-02-28","646556","2023-08-04","Division of Human and Animal Food Operations East V","William (Bill) Miller","2026-08-20T01:13:48.408+00:00","United Parcel Service","2023-02-03",{"id":103,"raw":104,"subject":109,"body_html":110,"body_text":111,"firm_name":112,"letter_id":113,"created_at":44,"fei_number":19,"letter_url":114,"updated_at":115,"action_type":22,"case_status":23,"posted_date":116,"marcs_cms_no":117,"product_type":73,"closeout_date":19,"issuing_office":108,"recipient_name":118,"body_fetched_at":119,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":120,"medical_device_id":19,"response_letter_date":19},2730,[105,106,107,108,109,13,13,13],"\u003Ctime datetime=\"2022-04-19T13:20:00Z\">04\u002F19\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-13T04:00:00Z\">04\u002F13\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fm-m-beauty-and-wellness-llc-628392-04132022\">M &amp; M Beauty and Wellness, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michelle Messer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>M &amp; M Beauty and Wellness, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>PO Box 204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Adel\u003C\u002Fspan>, \u003Cspan>IA\u003C\u002Fspan> \u003Cspan>50003\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:michelle@mandmbeautyandwellness.com\"> michelle@mandmbeautyandwellness.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: April 13, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Messer,\u003C\u002Fp>\n\n\u003Cp>This letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. BEST age spot remover lightening perfection crème drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug &amp; Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>BEST age spot remover lightening perfection crème is a drug as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\u003C\u002Fp>\n\n\u003Cp>Examples of the claims observed on your product label and from your website, www.mandmbeautyandwellness.com that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your product includes, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“BEST . . . age spot remover . . . lightening perfection crème . . . \u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Hydroquinone . . . 2.00% . . . Skin Lightener . . . \u003Cstrong>Uses:\u003C\u002Fstrong> Lightens dark spots in the skin such as freckles, age spots and liver spots.” [from your BEST age spot remover lightening perfection crème label]\u003C\u002Fp>\n\n\u003Cp>“\u003Cem>Best Age Spot Remover\u003C\u002Fem> . . . An advanced lightening skin cream containing maximum strength hydroquinone to gently fade skin discolorations along with a unique combination of plant extracts with very high de-pigmentation effectiveness.” [from your website www.mandmbeautyandwellness.com\u002Fbeauty\u002F]\u003C\u002Fp>\n\n\u003Cp>BEST age spot remover lightening perfection crème is a skin bleaching drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this skin bleaching product falls under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because it is subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Thus, BEST age spot remover lightening perfection crème is deemed to be a new drug under section 201(p)(1) of the FD&amp;C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&amp;C Act, 21 U.S.C. 355, beginning on September 23, 2020.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for BEST age spot remover lightening perfection crème. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a).\u003C\u002Fp>\n\n\u003Cp>Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act, 21 U.S.C. 331(d).\u003C\u002Fp>\n\n\u003Cp>Moreover, BEST age spot remover lightening perfection crème is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because it is deemed as such under section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&amp;C Act, 21 U.S.C. 355h.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations of the FD&amp;C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cbr>\n\u003Cbr>\nSpecify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(4) of the FD&amp;C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichelle Messer\n\nM & M Beauty and Wellness, LLC\n\nPO Box 204\n\nAdel, IA 50003\n\nUnited States\n\nmichelle@mandmbeautyandwellness.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: April 13, 2022\n\nDear Ms. Messer,\n\nThis letter concerns your firm’s distribution of a drug product to bleach and\u002For lighten the skin. BEST age spot remover lightening perfection crème drug product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the Federal Food Drug & Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), and is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of such product into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nUnapproved New Drug and Misbranded Drug Violations\n\nBEST age spot remover lightening perfection crème is a drug as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a skin bleaching product.\n\nExamples of the claims observed on your product label and from your website, www.mandmbeautyandwellness.com that provide evidence of the intended uses (as defined in 21 CFR 201.128) of your product includes, but may not be limited to, the following:\n\n“BEST . . . age spot remover . . . lightening perfection crème . . . Drug Facts . . . Hydroquinone . . . 2.00% . . . Skin Lightener . . . Uses: Lightens dark spots in the skin such as freckles, age spots and liver spots.” [from your BEST age spot remover lightening perfection crème label]\n\n“Best Age Spot Remover . . . An advanced lightening skin cream containing maximum strength hydroquinone to gently fade skin discolorations along with a unique combination of plant extracts with very high de-pigmentation effectiveness.” [from your website www.mandmbeautyandwellness.com\u002Fbeauty\u002F]\n\nBEST age spot remover lightening perfection crème is a skin bleaching drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. Specifically, this skin bleaching product falls under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), as added on March 27, 2020 with the enactment of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), because it is subject to a determination to be not generally recognized as safe and effective (GRASE) in a proposed rule that is the most recently applicable proposal issued under 21 CFR part 330.1 Thus, BEST age spot remover lightening perfection crème is deemed to be a new drug under section 201(p)(1) of the FD&C Act and subject to the requirement to have an approved new drug application for marketing under section 505 of the FD&C Act, 21 U.S.C. 355, beginning on September 23, 2020.2\n\nNo FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for BEST age spot remover lightening perfection crème. Accordingly, this skin bleaching drug product is an unapproved new drug and its introduction or delivery for introduction into interstate commerce violates section 505(a) of the FD&C Act, 21 U.S.C. 355(a).\n\nIntroduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) of the FD&C Act, 21 U.S.C. 331(d).\n\nMoreover, BEST age spot remover lightening perfection crème is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because it is deemed as such under section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), and because it is a nonprescription drug subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but is not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355, and does not comply with the requirements under section 505G of the FD&C Act, 21 U.S.C. 355h.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations regarding your products nor are the skin bleaching\u002Fskin lightening drug products named in this letter intended to be an all-inclusive list of products you have manufactured, registered, and\u002For listed in FDA’s electronic drug registration and listing system (eDRLS), or introduced into interstate commerce. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence and the occurrence of other violations. It is your responsibility to assure that your firm complies with all requirements of federal law and FDA regulations. You should take prompt action to correct the violations cited in this letter. Failure to promptly correct any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nFailure to address violations of the FD&C Act may be cause for FDA to withhold approval of requests for export certificates and approval of pending new drug applications or supplements listing your facility as a supplier or manufacturer.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\n\nSpecify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address violations within 15 working days, state your reasons for delay and schedule for completion.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease direct your email response to Office of Unapproved Drugs and Labeling Compliance at the following email address to FDAADVISORY@fda.hhs.gov and include your firm name in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\ncc:\n\n(b)(4)\n\n___________________________\n\n1 On August 29, 2006, FDA issued a proposed rule (71 FR 51146) setting forth a determination that OTC skin bleaching drug products, including but not limited to those that contain hydroquinone as an active ingredient, are not generally recognized as safe and effective.\n\n2 Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4), authorized FDA to take action before September 23, 2020 to extend the period during which a drug subject to that section may be marketed without an approved new drug application if the Agency determined that such an extension is in the interest of public health. However, FDA did not make such a determination for skin bleaching products.","M & M Beauty and Wellness, LLC","m-m-beauty-and-wellness-llc-628392-04132022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fm-m-beauty-and-wellness-llc-628392-04132022","2026-10-26T08:09:17.890362+00:00","2022-04-19","628392","Michelle Messer","2026-08-20T01:59:47.918+00:00","2022-04-13",{"id":122,"raw":123,"subject":38,"body_html":129,"body_text":130,"firm_name":131,"letter_id":132,"created_at":133,"fei_number":19,"letter_url":134,"updated_at":135,"action_type":22,"case_status":47,"posted_date":136,"marcs_cms_no":137,"product_type":138,"closeout_date":139,"issuing_office":127,"recipient_name":140,"body_fetched_at":141,"delivery_method":142,"recipient_title":19,"reference_number":19,"action_taken_date":143,"medical_device_id":19,"response_letter_date":19},3431,[124,125,126,127,38,13,128,13],"\u003Ctime datetime=\"2021-03-30T13:20:00Z\">03\u002F30\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-16T04:00:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanna-health-llc-613294-03162021\">Anna Health, LLC\u003C\u002Fa>","Division of Human and Animal Food Operations East IV","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanna-health-llc-613294-04042022\">\u003Ctime datetime=\"2022-04-08T04:00:00Z\">04\u002F08\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Tin Huynh\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Registered Agent\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Anna Health, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9724 N. Armenia Ave. Suite 400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tampa\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33612-7550\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:TinHuynh@gmail.com\"> TinHuynh@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Human and Animal Food Operations East IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>21-HAFE4-WL-03 \u002F CMS No. 613294\u003Cbr>\n\u003Cbr>\nDear Mr. Huynh:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that from October 2020 to March 2021, the United States Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.annahealth.com, and has determined that you take orders there for the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health. In addition, we observed that the product Immune Health is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. The claims on your website establish that the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are drugs under section 201 (g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), [21 U.S.C 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's homepage at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>On the website www.annahealth.com:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Fucoidan product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Fucoidan is a powerful anticancerous supplement from the Sea.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan…triggers the natural immune system to attack and kill cancer cells.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan suppresses the generation of new blood vessels around cancer cells, cutting off their nutrient supply. This also prevents the cancer cells from spreading.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan provides an anticancer effect by way of inducing apoptosis.”\u003C\u002Fli>\n\t\u003Cli>“Fucoidan reduces side effects of chemotherapy and radiation.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Prostate Health product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Improves…urinary flow.”\u003C\u002Fli>\n\t\u003Cli>“Relieves symptoms of BPH (Enlarged Prostate).”\u003C\u002Fli>\n\t\u003Cli>“Protects against prostate cancer.”\u003C\u002Fli>\n\t\u003Cli>“Reduces urinary urgency.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Under the tab “Main Ingredients”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Fritillaria Bulb (Zhe bei mu) …dissipates nodules…antitussive…reduces blood pressure”\u003C\u002Fli>\n\t\u003Cli>“Serenoa Repens (Saw palmetto) …treatment of benign prostatic hyperplasia (BPH)…reduces urinary problems…useful with prostate cancer”\u003C\u002Fli>\n\t\u003Cli>“Rhizoma Chuanxiong (Chuan xiong) …relieves headache…”\u003C\u002Fli>\n\t\u003Cli>“Angelica Sinensis (Dang gui) …treats painful obstructive syndromes…treats headache”\u003C\u002Fli>\n\t\u003Cli>“Cinnamonum Zeylanicum (Gui zhi) …reduces cholesterol level…antimicrobial…regulates blood sugar…reduces arthritis pain, joints [sic] pain”\u003C\u002Fli>\n\t\u003Cli>“Amur Corktree (Huang bai) …prevents prostate enlargement…reduces inflammation…anti-cancer”\u003C\u002Fli>\n\t\u003Cli>“Panax Quinquefolius (Xi yang shen) …repairs internal damage due to prolong stress…”\u003C\u002Fli>\n\t\u003Cli>“Radix Glycyrrhizae Uralensis (Gan cao) …reduces cough…relieves fever…”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Children Liquid Vitamins product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Eliminates children symptoms of anemia, anorexia…”\u003C\u002Fli>\n\t\u003Cli>“[R]educes anxiety and attention deficit.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Under the tab “Main Ingredients”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Dipsacus Asper Radix (Xu duan)…relieves back pain”\u003C\u002Fli>\n\t\u003Cli>“Radix Rehmanniae Preparata (Sheng di) …treats anemic symptoms…antiinflammation… reduces hypertension, hyperlipidemia”\u003C\u002Fli>\n\t\u003Cli>“Radix Polygoni Multiflori (He shou wu) … treats anemia…calms hyperactive, treats insomnia…”\u003C\u002Fli>\n\t\u003Cli>“Ganoderma Lucidum (Fruit bodies with Opened Spores, Ling zhi) …antiviral…anticancer”\u003C\u002Fli>\n\t\u003Cli>“Fresh Royal Jelly (non-freeze dried) …anti-depression”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>Immune Health product:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“COVID-19 Influenza”\u003C\u002Fli>\n\t\u003Cli>“Helps Boost Your Immune System Against: Coronavirus…Influenza…Bronchitis…Dyspnea…Common Cold”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003Cbr>\n\u003Cbr>\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be directed to Mr. Ramon A. Hernandez, District Director\u002FProgram Division Director, Food and Drug Administration, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact LCDR Laura Kennedy, Compliance Officer, at \u003Cspan>(813) 915-7948\u003Cspan>\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>\u003C\u002Fspan> or Laura.Kennedy@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ramon A. Hernandez\u003Cbr>\nDistrict Director, San Juan District\u003Cbr>\nProgram Division Director,\u003Cbr>\nOffice of Human and Animal Food Operations,\u003Cbr>\nEast Division IV\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Tin Huynh\n\nRecipient Title\n\nRegistered Agent\n\nAnna Health, LLC\n\n9724 N. Armenia Ave. Suite 400\n\nTampa, FL 33612-7550\n\nUnited States\n\nTinHuynh@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East IV\n\nUnited States\n\nWARNING LETTER\n\n21-HAFE4-WL-03 \u002F CMS No. 613294\n\nDear Mr. Huynh:\n\nThis is to advise you that from October 2020 to March 2021, the United States Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fwww.annahealth.com, and has determined that you take orders there for the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health. In addition, we observed that the product Immune Health is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. The claims on your website establish that the products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are drugs under section 201 (g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act), [21 U.S.C 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA's homepage at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn the website www.annahealth.com:\n\nFucoidan product:\n\n“Fucoidan is a powerful anticancerous supplement from the Sea.”\n\n“Fucoidan…triggers the natural immune system to attack and kill cancer cells.”\n\n“Fucoidan suppresses the generation of new blood vessels around cancer cells, cutting off their nutrient supply. This also prevents the cancer cells from spreading.”\n\n“Fucoidan provides an anticancer effect by way of inducing apoptosis.”\n\n“Fucoidan reduces side effects of chemotherapy and radiation.”\n\nProstate Health product:\n\n“Improves…urinary flow.”\n\n“Relieves symptoms of BPH (Enlarged Prostate).”\n\n“Protects against prostate cancer.”\n\n“Reduces urinary urgency.”\n\nUnder the tab “Main Ingredients”:\n\n“Fritillaria Bulb (Zhe bei mu) …dissipates nodules…antitussive…reduces blood pressure”\n\n“Serenoa Repens (Saw palmetto) …treatment of benign prostatic hyperplasia (BPH)…reduces urinary problems…useful with prostate cancer”\n\n“Rhizoma Chuanxiong (Chuan xiong) …relieves headache…”\n\n“Angelica Sinensis (Dang gui) …treats painful obstructive syndromes…treats headache”\n\n“Cinnamonum Zeylanicum (Gui zhi) …reduces cholesterol level…antimicrobial…regulates blood sugar…reduces arthritis pain, joints [sic] pain”\n\n“Amur Corktree (Huang bai) …prevents prostate enlargement…reduces inflammation…anti-cancer”\n\n“Panax Quinquefolius (Xi yang shen) …repairs internal damage due to prolong stress…”\n\n“Radix Glycyrrhizae Uralensis (Gan cao) …reduces cough…relieves fever…”\n\nChildren Liquid Vitamins product:\n\n“Eliminates children symptoms of anemia, anorexia…”\n\n“[R]educes anxiety and attention deficit.”\n\nUnder the tab “Main Ingredients”:\n\n“Dipsacus Asper Radix (Xu duan)…relieves back pain”\n\n“Radix Rehmanniae Preparata (Sheng di) …treats anemic symptoms…antiinflammation… reduces hypertension, hyperlipidemia”\n\n“Radix Polygoni Multiflori (He shou wu) … treats anemia…calms hyperactive, treats insomnia…”\n\n“Ganoderma Lucidum (Fruit bodies with Opened Spores, Ling zhi) …antiviral…anticancer”\n\n“Fresh Royal Jelly (non-freeze dried) …anti-depression”\n\nImmune Health product:\n\n“COVID-19 Influenza”\n\n“Helps Boost Your Immune System Against: Coronavirus…Influenza…Bronchitis…Dyspnea…Common Cold”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the Fucoidan, Prostate Health, Children Liquid Vitamins, and Immune Health products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action, including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be directed to Mr. Ramon A. Hernandez, District Director\u002FProgram Division Director, Food and Drug Administration, 466 Fernández Juncos Avenue, San Juan, Puerto Rico 00901-3223. If you have any questions regarding this letter, please contact LCDR Laura Kennedy, Compliance Officer, at (813) 915-7948 or Laura.Kennedy@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRamon A. Hernandez\n\nDistrict Director, San Juan District\n\nProgram Division Director,\n\nOffice of Human and Animal Food Operations,\n\nEast Division IV\n\n__________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell a product that is intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.","Anna Health, LLC","anna-health-llc-613294-03162021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fanna-health-llc-613294-03162021","2026-10-26T08:07:56.035163+00:00","2021-03-30","613294","Dietary SupplementsDrugs","2022-04-08","Mr. Tin Huynh","2026-08-20T03:14:19.258+00:00","VIA Electronic Mail","2021-03-16",{"id":145,"raw":146,"subject":151,"body_html":153,"body_text":154,"firm_name":155,"letter_id":156,"created_at":133,"fei_number":19,"letter_url":157,"updated_at":158,"action_type":22,"case_status":47,"posted_date":159,"marcs_cms_no":160,"product_type":161,"closeout_date":162,"issuing_office":150,"recipient_name":163,"body_fetched_at":164,"delivery_method":100,"recipient_title":19,"reference_number":19,"action_taken_date":165,"medical_device_id":19,"response_letter_date":19},3153,[147,148,149,150,151,13,152,13],"\u003Ctime datetime=\"2021-09-09T14:50:00Z\">09\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-07T04:00:00Z\">09\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fholistic-healer-wellness-center-inc-614538-09072021\">Holistic Healer &amp; Wellness Center, Inc. \u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Unapproved New Drugs\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fholistic-healer-wellness-center-inc-614538-03152022\">\u003Ctime datetime=\"2022-03-21T04:00:00Z\">03\u002F21\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Stacy Sanchez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Holistic Healer &amp; Wellness Center, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3998 Clippert St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>P.O. Box 23017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dearborn\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48123\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: 614538\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Stacy Sanchez:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website athttps:\u002F\u002Fholistichealeronline.com\u002F in August 2021 and has determined that you take orders there for your Diabalance Diabetes Supplement product. You are also advised that the Federal Trade Commission reviewed your website in August 2021.\u003C\u002Fp>\n\n\u003Cp>The claims on your website establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>• “Diabalance Diabetes Supplement” (Product name)\u003Cbr>\n• “The key ingredients are a helpful aid to people who have diabetes and hypoglycemia.”\u003Cbr>\n• “Blood sugar rises. . .It may lower elevated blood pressure. . .”\u003Cbr>\n• “The Bitter Melon, Dandelion, Bilberry and Ginkgo biloba in this vegetarian capsule helps balance blood sugar levels for people with diabetes.”\u003Cbr>\n• “The combination of these ingredients helps with blood sugar control. . .”\u003Cbr>\n• “Works great to lower high blood sugar. . .”\u003Cbr>\n• “We recommend people with type 2 diabetes or those who are experiencing insulin resistance to opt for this holistic diabetes treatment.”\u003Cbr>\n• “For those with type 2 diabetes. . .”\u003C\u002Fp>\n\n\u003Cp>Your Diabalance Diabetes Supplement product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Diabalance Diabetes Supplement is intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self‐diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Diabalance Diabetes Supplement fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all‐inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply to the above violations should be directed to Rob Genzel Jr. with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>FTC Cease and Desist Demand:\u003C\u002Fstrong> In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well‐controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60‐61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16‐19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx.505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297‐99 (1988), aff’d, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06‐6112‐JFW, 2007‐2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11‐12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17‐19.\u003C\u002Fp>\n\n\u003Cp>The FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. Notice is hereby given that you must cease and desist from making any claim that a product and prevent, treat, or cure diabetes without competent and reliable scientific evidence consisting of well‐controlled human clinical studies substantiating that the claims are true. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.gov within fifteen (15) working days of receipt of this letter of the specific actions you have taken to address FTC's concerns.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nGlenn Bass\u003Cbr>\nActing Deputy Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nSerena Viswanathan\u003Cbr>\nAssociate Director\u003Cbr>\nDivision of Advertising Practices\u003Cbr>\nFederal Trade Commission\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDietary Supplements\n\nRecipient:\n\nRecipient Name\n\nStacy Sanchez\n\nHolistic Healer & Wellness Center, Inc.\n\n3998 Clippert St.\n\nP.O. Box 23017\n\nDearborn, MI 48123\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: 614538\n\nDear Ms. Stacy Sanchez:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website athttps:\u002F\u002Fholistichealeronline.com\u002F in August 2021 and has determined that you take orders there for your Diabalance Diabetes Supplement product. You are also advised that the Federal Trade Commission reviewed your website in August 2021.\n\nThe claims on your website establish that this product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your product is intended for use as a drug include:\n\n• “Diabalance Diabetes Supplement” (Product name)\n\n• “The key ingredients are a helpful aid to people who have diabetes and hypoglycemia.”\n\n• “Blood sugar rises. . .It may lower elevated blood pressure. . .”\n\n• “The Bitter Melon, Dandelion, Bilberry and Ginkgo biloba in this vegetarian capsule helps balance blood sugar levels for people with diabetes.”\n\n• “The combination of these ingredients helps with blood sugar control. . .”\n\n• “Works great to lower high blood sugar. . .”\n\n• “We recommend people with type 2 diabetes or those who are experiencing insulin resistance to opt for this holistic diabetes treatment.”\n\n• “For those with type 2 diabetes. . .”\n\nYour Diabalance Diabetes Supplement product is not generally recognized as safe and effective for the above referenced uses and, therefore, this product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Diabalance Diabetes Supplement is intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self‐diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Diabalance Diabetes Supplement fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all‐inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address these matters may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply to the above violations should be directed to Rob Genzel Jr. with the FDA via email at CFSANResponse@fda.hhs.gov. If you have any questions, you may also email at CFSANResponse@fda.hhs.gov.\n\nFTC Cease and Desist Demand: In addition, the Federal Trade Commission has determined that it is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess a reasonable basis consisting of competent and reliable scientific evidence, including, when appropriate, well‐controlled human clinical studies, substantiating that the claims are true at the time they are made. POM Wonderful LLC, 155 F.T.C. 1, 60‐61, (2013), aff’d in relevant part, 777 F.3d 478 (D.C. Cir. 2015); Daniel Chapter One, FTC Dkt. No. 9239, 2009 WL 5160000 at *16‐19 (F.T.C. Dec. 24, 2009), aff’d, 405 Fed. Appx.505 (D.C. Cir. 2010); Removatron Int'l Corp., 111 F.T.C. 206, 297‐99 (1988), aff’d, 884 F.2d 1489, 1496 (1st Cir. 1989); see also, FTC v. Direct Mktg. Concepts, 569 F. Supp. 2d 285, 300, 303 (D. Mass. 2008), aff’d, 624 F.3d 1 (1st Cir. 2010); FTC v. Nat'l Urological Group, Inc., 645 F. Supp. 2d 1167, 1190, 1202 (N.D. Ga. 2008), aff’d, 356 Fed. Appx. 358 (11th Cir. 2009); FTC v. Natural Solution, Inc., No. CV 06‐6112‐JFW, 2007‐2 Trade Cas. (CCH) P75,866, 2007 U.S. Dist. LEXIS 60783, at *11‐12 (C.D. Cal. Aug. 7, 2007). More generally, to make or exaggerate such claims, whether directly or indirectly, through the use of a product name, website name, metatags, or other means, without rigorous scientific evidence sufficient to substantiate the claims, violates the FTC Act. See Daniel Chapter One, WL 5160000 at *17‐19.\n\nThe FTC is concerned that one or more of the efficacy claims cited above may not be substantiated by competent and reliable scientific evidence. Notice is hereby given that you must cease and desist from making any claim that a product and prevent, treat, or cure diabetes without competent and reliable scientific evidence consisting of well‐controlled human clinical studies substantiating that the claims are true. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction or Administrative Cease and Desist Order. In addition, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of a disease may be subject to a civil penalty of up to $43,792 per violation pursuant to Section 5(m)(1)(B) of the FTC Act, 15 U.S.C. § 45(m)(1)(B), and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). With regard to the advertising claims discussed above, please notify Richard Cleland of the FTC via electronic mail at rcleland@ftc.gov within fifteen (15) working days of receipt of this letter of the specific actions you have taken to address FTC's concerns.\n\nSincerely,\n\n\u002FS\u002F\n\nGlenn Bass\n\nActing Deputy Director\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission","Holistic Healer & Wellness Center, Inc.","holistic-healer-wellness-center-inc-614538-09072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fholistic-healer-wellness-center-inc-614538-09072021","2026-10-26T08:08:55.285018+00:00","2021-09-09","614538","Dietary Supplements","2022-03-21","Stacy Sanchez","2026-08-20T02:36:33.675+00:00","2021-09-07",{"id":167,"raw":168,"subject":38,"body_html":173,"body_text":174,"firm_name":175,"letter_id":176,"created_at":133,"fei_number":19,"letter_url":177,"updated_at":178,"action_type":22,"case_status":23,"posted_date":179,"marcs_cms_no":180,"product_type":181,"closeout_date":19,"issuing_office":172,"recipient_name":182,"body_fetched_at":183,"delivery_method":142,"recipient_title":19,"reference_number":19,"action_taken_date":184,"medical_device_id":19,"response_letter_date":19},3363,[169,170,171,172,38,13,13,13],"\u003Ctime datetime=\"2021-05-11T13:20:00Z\">05\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-29T04:00:00Z\">04\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcrown-wellness-inc-610844-04292021\">Crown Wellness, Inc \u003C\u002Fa>","Center for Food Safety and Applied Nutrition","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kevin Lockhart\u002FDavid Black\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Crown Wellness, Inc \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>118 Middle Street, Suite 1020\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lake Mary\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32746\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Drug Evaluation and Research\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 29, 2021\u003C\u002Fp>\n\n\u003Cp>Crown Wellness, Inc.\u003Cbr>\nDavid Black, President\u003Cbr>\n421 Grand Concourse #1\u003Cbr>\nMiami Shores, FL 33183\u003C\u002Fp>\n\n\u003Cp>Crown Wellness, Inc.\u003Cbr>\nDavid Black, President\u003Cbr>\n9999 NE 2 Ave, Suite 209E\u003Cbr>\nMiami Shores, FL 33138\u003C\u002Fp>\n\n\u003Cp>Re: 610844\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Lockhart and Mr. Black:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.crownwellness.com in February and March 2021 and has determined that you take orders there for the products Clinic’s Choice CLO2, E3 Renew Me\u002FB.G. Blue Green Algae, Diatomaceous Earth Powder (DE), E3 Digestive Enzymes Supreme, Karma Cleanse, and Iodine Detoxified. The claims on your website and product labels establish that the products are drugs under section 201(g)(1)(B) and\u002For (g)(1)(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B) and\u002For (g)(1)(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or any function of the body. Furthermore, your Clinic’s Choice CLO2 is intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You may find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims on your website and product labels that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Clinic’s Choice CLO2:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fclo2\u002F:\u003C\u002Fp>\n\n\u003Cp>o There is a video on that webpage, titled “Over 100 Recoverded [sic] from Covid-19 with CLO2.” This video is also posted on your website at https:\u002F\u002Fcrownwellness.com\u002Fover-100-recoverded-from-covid-19-with-clo2\u002F:\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp> [At 00:23] “with this video I want to publish officially the first success of treatment against coronavirus or COVID-19 with more than 100 affected people recovered after only four days.”\u003Cbr>\n [At 00:53] “Chlorine Dioxide or CLO2 is a substance known as the best disinfectant against viruses, fungi, bacteria . . .”\u003Cbr>\n [At 03:08] “. . . and this is the true reason for the success of CDS against coronavirus.”\u003Cbr>\n [At 03:45] “a few months ago I published the fact that Chlorine Dioxide in the form of CDS works perfectly in the most serious problem of today which is the so-called coronavirus pandemic, it is not a theory it is an irrefutable fact . . .”\u003Cbr>\n [At 06:50] “. . . showing in an irrefutable way that Chlorine Dioxide does work for the treatment of coronavirus and does not cause negative side effects . . .”\u003C\u002Fp>\n\n\u003Cp>o The product is listed as being in the following categories, “Arthritis\u002FInflammation” and Autism”.\u003Cbr>\no “Our proprietary product CLO2 (also known as Chlorine Dioxide) is a powerful anti-viral, anti-fungal and anti-bacterial liquid. It helps eradicate the weak blood cells from your body that are susceptible to infection.”\u003Cbr>\no “This product is used for bacterial \u002Ffungal infections and for the possible eradication of yeast, parasites and Morgellon’s.”\u003C\u002Fp>\n\n\u003Cp>• On your product’s label:\u003C\u002Fp>\n\n\u003Cp>o “Clinic’s Choice CL O2 PRIME DEFENSE . . . Bacterial\u002FFungal Forms and Parasite Eradication”\u003C\u002Fp>\n\n\u003Cp>• Clinic’s’ Choice CLO2 is listed under the “Autism” tab on your Shop page at https:\u002F\u002Fcrownwellness.com\u002Fproduct-category\u002Fautism\u002F.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Diatomaceous Earth Powder (DE):\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fdiatomaceous-earth-de-1-gallon\u002F:\u003C\u002Fp>\n\n\u003Cp>o The product is listed as being in the following categories, “Arthritis\u002FInflammation” and “Fungal”.\u003C\u002Fp>\n\n\u003Cp>• On your product’s label:\u003C\u002Fp>\n\n\u003Cp>o BENEFITS\u003Cbr>\n “Kills worms or parasites”\u003Cbr>\n “Lowers Bad Cholesterol”\u003Cbr>\n “Sweeps Bacteria”\u003Cbr>\n “Maintains Elasticity of Lung Tissue”\u003Cbr>\n “Reduces Inflammation”\u003Cbr>\n “Tones Respiratory Tract”\u003Cbr>\n “Positive Action on the Lymphatic System”\u003Cbr>\n “Helps Prevent Kidney Stones and Heal Infections of the Urinary Tract”\u003Cbr>\n “Reduces inflammation of Intestines”\u003Cbr>\n “Helps with Stomach and Intestinal mucus and ulcers”\u003Cbr>\n “Clears up Diarrhea and its opposite constipation”\u003Cbr>\n “Helps Normalize Hemorrhoidal Tissue”\u003Cbr>\n “Normalize Bowels”\u003Cbr>\n “Effective with Female discharge, abscesses and ulcer in the Genital area and Cervix”\u003Cbr>\n “Helps with inflammation of the Middle Ear”\u003Cbr>\n “Helps Reduce swelling of the Lymph nodes in the throat”\u003Cbr>\n “Circulation and Regulates High Blood Pressure (hypertension)”\u003Cbr>\n “Vertigo, Tinnitus (buzzing of the ears) and Insomnia”\u003Cbr>\n “Helps with Diabetes”\u003Cbr>\n “Arterial Disease by Strengthening the Blood Vessels”\u003Cbr>\n “Helps Prevent Tuberculosis”\u003Cbr>\n “Elasticity of the Joints, Silica helps Rheumatism”\u003Cbr>\n “Coronary Diseases”\u003Cbr>\n “Alzheimers [sic]”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E3 Renew Me\u002FB.G. Blue Green Algae\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fe3live-renew-b-g-algae-300-caps\u002F:\u003C\u002Fp>\n\n\u003Cp>o The product is listed as being in the “Fungal” category.\u003C\u002Fp>\n\n\u003Cp>• On your “About Us” page at https:\u002F\u002Fcrownwellness.com\u002Fabout-clinics-choice\u002F, which links to your online shop:\u003C\u002Fp>\n\n\u003Cp>o “The Body has an amazing ability to Heal itself – cancer and most chronic degenerative diseases are not only preventable but also reversible. . . .\u003C\u002Fp>\n\n\u003Cp>If someone has cancer it is true that the bad cells have overtaken the good ones. We use natural supplements to stimulate the good cells to overtake the bad. For example, Renew Me (from blue-green algae) is a multimineral that helps stimulate Healthy white blood cells, which even traditional medicine believes is your immune system’s first line of defense.”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E3 Digestive Enzyme Supreme:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fe3live-enzymes-supreme-240-caps-2\u002F:\u003C\u002Fp>\n\n\u003Cp>o The product is listed as being in the following categories, “Arthritis\u002FInflammation” and ”Fungal”\u003Cbr>\no “relief for . . . indigestion . . .”\u003C\u002Fp>\n\n\u003Cp>This website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\u003C\u002Fp>\n\n\u003Cp>• “. . . I was diagnosed with COPD stage 3…I was blessed to find a product that worked within one week for me… I started with 5 or 6 products from this company . . . On the first week HALF of my COPD systems [sic] went away . . . I will CONTINUE . . . to take . . . E3 Renew Me..Bio Command 4, Diatomaceous Earth powder (DE), . . . E3 Probiotics &amp; Iodine Detoxified . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . I had fatigue and digestive problems after my gall bladder removal. I have been using DE, E3Live Renew Me, E3 Digestive Enzymes, CLO2, Karma Cleanser . . . on and off for the past year and everytime I stop for a couple months my body aches and my digestive problems begin . . .”\u003C\u002Fp>\n\n\u003Cp>• “The RenewMe is amazing (I have barely suffered a flu or cold for two years).”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Clinic’s Choice CLO2, E3 Renew Me\u002FB.G. Blue Green Algae, Diatomaceous Earth Powder (DE), and Iodine Detoxified are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Clinic’s Choice CLO2, E3 Renew Me\u002FB.G. Blue Green Algae, Diatomaceous Earth Powder (DE), and Iodine Detoxified fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written reply should be directed to FDAAdvisory@fda.hhs.gov. If you have questions regarding any issues in this letter, please contact this e-mail address.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Michael W. Roosevelt\u003Cbr>\nActing Director\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donald D. Ashley\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We note that, as of the date of this letter, the claims cited above regarding COVID-19 appear to have been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nKevin Lockhart\u002FDavid Black\n\nRecipient Title\n\nPresident\n\nCrown Wellness, Inc\n\n118 Middle Street, Suite 1020\n\nLake Mary, FL 32746\n\nUnited States\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition\n\nUnited States\n\nCenter for Drug Evaluation and Research\n\nWARNING LETTER\n\nApril 29, 2021\n\nCrown Wellness, Inc.\n\nDavid Black, President\n\n421 Grand Concourse #1\n\nMiami Shores, FL 33183\n\nCrown Wellness, Inc.\n\nDavid Black, President\n\n9999 NE 2 Ave, Suite 209E\n\nMiami Shores, FL 33138\n\nRe: 610844\n\nDear Mr. Lockhart and Mr. Black:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.crownwellness.com in February and March 2021 and has determined that you take orders there for the products Clinic’s Choice CLO2, E3 Renew Me\u002FB.G. Blue Green Algae, Diatomaceous Earth Powder (DE), E3 Digestive Enzymes Supreme, Karma Cleanse, and Iodine Detoxified. The claims on your website and product labels establish that the products are drugs under section 201(g)(1)(B) and\u002For (g)(1)(C) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B) and\u002For (g)(1)(C)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease and\u002For because they are intended to affect the structure or any function of the body. Furthermore, your Clinic’s Choice CLO2 is intended to mitigate, prevent, treat, diagnose, or cure COVID-191 in people. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You may find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the claims on your website and product labels that provide evidence that your products are intended for use as drugs include:\n\nClinic’s Choice CLO2:\n\n• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fclo2\u002F:\n\no There is a video on that webpage, titled “Over 100 Recoverded [sic] from Covid-19 with CLO2.” This video is also posted on your website at https:\u002F\u002Fcrownwellness.com\u002Fover-100-recoverded-from-covid-19-with-clo2\u002F:2\n\n [At 00:23] “with this video I want to publish officially the first success of treatment against coronavirus or COVID-19 with more than 100 affected people recovered after only four days.”\n\n [At 00:53] “Chlorine Dioxide or CLO2 is a substance known as the best disinfectant against viruses, fungi, bacteria . . .”\n\n [At 03:08] “. . . and this is the true reason for the success of CDS against coronavirus.”\n\n [At 03:45] “a few months ago I published the fact that Chlorine Dioxide in the form of CDS works perfectly in the most serious problem of today which is the so-called coronavirus pandemic, it is not a theory it is an irrefutable fact . . .”\n\n [At 06:50] “. . . showing in an irrefutable way that Chlorine Dioxide does work for the treatment of coronavirus and does not cause negative side effects . . .”\n\no The product is listed as being in the following categories, “Arthritis\u002FInflammation” and Autism”.\n\no “Our proprietary product CLO2 (also known as Chlorine Dioxide) is a powerful anti-viral, anti-fungal and anti-bacterial liquid. It helps eradicate the weak blood cells from your body that are susceptible to infection.”\n\no “This product is used for bacterial \u002Ffungal infections and for the possible eradication of yeast, parasites and Morgellon’s.”\n\n• On your product’s label:\n\no “Clinic’s Choice CL O2 PRIME DEFENSE . . . Bacterial\u002FFungal Forms and Parasite Eradication”\n\n• Clinic’s’ Choice CLO2 is listed under the “Autism” tab on your Shop page at https:\u002F\u002Fcrownwellness.com\u002Fproduct-category\u002Fautism\u002F.\n\nDiatomaceous Earth Powder (DE):\n\n• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fdiatomaceous-earth-de-1-gallon\u002F:\n\no The product is listed as being in the following categories, “Arthritis\u002FInflammation” and “Fungal”.\n\n• On your product’s label:\n\no BENEFITS\n\n “Kills worms or parasites”\n\n “Lowers Bad Cholesterol”\n\n “Sweeps Bacteria”\n\n “Maintains Elasticity of Lung Tissue”\n\n “Reduces Inflammation”\n\n “Tones Respiratory Tract”\n\n “Positive Action on the Lymphatic System”\n\n “Helps Prevent Kidney Stones and Heal Infections of the Urinary Tract”\n\n “Reduces inflammation of Intestines”\n\n “Helps with Stomach and Intestinal mucus and ulcers”\n\n “Clears up Diarrhea and its opposite constipation”\n\n “Helps Normalize Hemorrhoidal Tissue”\n\n “Normalize Bowels”\n\n “Effective with Female discharge, abscesses and ulcer in the Genital area and Cervix”\n\n “Helps with inflammation of the Middle Ear”\n\n “Helps Reduce swelling of the Lymph nodes in the throat”\n\n “Circulation and Regulates High Blood Pressure (hypertension)”\n\n “Vertigo, Tinnitus (buzzing of the ears) and Insomnia”\n\n “Helps with Diabetes”\n\n “Arterial Disease by Strengthening the Blood Vessels”\n\n “Helps Prevent Tuberculosis”\n\n “Elasticity of the Joints, Silica helps Rheumatism”\n\n “Coronary Diseases”\n\n “Alzheimers [sic]”\n\nE3 Renew Me\u002FB.G. Blue Green Algae\n\n• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fe3live-renew-b-g-algae-300-caps\u002F:\n\no The product is listed as being in the “Fungal” category.\n\n• On your “About Us” page at https:\u002F\u002Fcrownwellness.com\u002Fabout-clinics-choice\u002F, which links to your online shop:\n\no “The Body has an amazing ability to Heal itself – cancer and most chronic degenerative diseases are not only preventable but also reversible. . . .\n\nIf someone has cancer it is true that the bad cells have overtaken the good ones. We use natural supplements to stimulate the good cells to overtake the bad. For example, Renew Me (from blue-green algae) is a multimineral that helps stimulate Healthy white blood cells, which even traditional medicine believes is your immune system’s first line of defense.”\n\nE3 Digestive Enzyme Supreme:\n\n• On your product’s page at https:\u002F\u002Fcrownwellness.com\u002Fproduct\u002Fe3live-enzymes-supreme-240-caps-2\u002F:\n\no The product is listed as being in the following categories, “Arthritis\u002FInflammation” and ”Fungal”\n\no “relief for . . . indigestion . . .”\n\nThis website also contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the cure, mitigation, treatment, or prevention of disease. Examples of such testimonials include:\n\n• “. . . I was diagnosed with COPD stage 3…I was blessed to find a product that worked within one week for me… I started with 5 or 6 products from this company . . . On the first week HALF of my COPD systems [sic] went away . . . I will CONTINUE . . . to take . . . E3 Renew Me..Bio Command 4, Diatomaceous Earth powder (DE), . . . E3 Probiotics & Iodine Detoxified . . .”\n\n• “. . . I had fatigue and digestive problems after my gall bladder removal. I have been using DE, E3Live Renew Me, E3 Digestive Enzymes, CLO2, Karma Cleanser . . . on and off for the past year and everytime I stop for a couple months my body aches and my digestive problems begin . . .”\n\n• “The RenewMe is amazing (I have barely suffered a flu or cold for two years).”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Clinic’s Choice CLO2, E3 Renew Me\u002FB.G. Blue Green Algae, Diatomaceous Earth Powder (DE), and Iodine Detoxified are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Clinic’s Choice CLO2, E3 Renew Me\u002FB.G. Blue Green Algae, Diatomaceous Earth Powder (DE), and Iodine Detoxified fail to bear adequate directions for their intended uses and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written reply should be directed to FDAAdvisory@fda.hhs.gov. If you have questions regarding any issues in this letter, please contact this e-mail address.\n\nSincerely,\n\n\u002FS\u002F\n\nMichael W. Roosevelt\n\nActing Director\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n_________________________\n\n1 There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS. Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx. In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19. Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F. Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\n2 We note that, as of the date of this letter, the claims cited above regarding COVID-19 appear to have been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.","Crown Wellness, Inc","crown-wellness-inc-610844-04292021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcrown-wellness-inc-610844-04292021","2026-10-26T08:08:19.299845+00:00","2021-05-11","610844","DrugsFood & Beverages","Kevin Lockhart\u002FDavid Black","2026-08-20T03:08:44.127+00:00","2021-04-29",8,{"510k":187,"classification":188,"enforcement":189,"event":190,"event_backfill":191,"pma":192,"warning_letter":193},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]